Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,050,000 shares, a growth of 5.7% from the February 13th total of 1,940,000 shares. Based on an average daily volume of 324,300 shares, the short-interest ratio is currently 6.3 days. Approximately 5.5% of the company’s shares are short sold.
Insider Buying and Selling
In other news, CFO Glenna Mileson acquired 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 28th. The stock was purchased at an average price of $2.85 per share, with a total value of $142,500.00. Following the purchase, the chief financial officer now owns 159,930 shares of the company’s stock, valued at approximately $455,800.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 14.90% of the company’s stock.
Institutional Investors Weigh In On Athira Pharma
A number of institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. boosted its stake in shares of Athira Pharma by 6.9% during the 4th quarter. Alliancebernstein L.P. now owns 81,900 shares of the company’s stock valued at $260,000 after buying an additional 5,300 shares during the period. State of Wisconsin Investment Board bought a new position in shares of Athira Pharma during the 4th quarter valued at $48,000. Squarepoint Ops LLC bought a new position in shares of Athira Pharma during the 4th quarter valued at $55,000. Tang Capital Management LLC bought a new position in shares of Athira Pharma during the 4th quarter valued at $1,538,000. Finally, Millennium Management LLC raised its holdings in shares of Athira Pharma by 27.8% during the 4th quarter. Millennium Management LLC now owns 36,426 shares of the company’s stock valued at $115,000 after purchasing an additional 7,914 shares in the last quarter. Institutional investors and hedge funds own 58.67% of the company’s stock.
Athira Pharma Stock Down 3.6 %
About Athira Pharma
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.
- Get a free copy of the StockNews.com research report on Athira Pharma (ATHA)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.